Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The increasing tuberculosis (TB) disease prevalence is a major factor that is expected to drive growth of the global pyrazinamide market. For instance, according to the National Center for Biotechnology Information in 2019, total 8,920 number of TB disease new cases were provisionally reported in the U.S. according to same source, the rate of TB is around 2.7 per 100,000 persons. Moreover, TB is a major burden across the globe. According to TB Facts report organization data, in 2018, in the U.S, the cost of treating drug sensitive TB was US$ 49,000; treatment costs for MDR-TB averaged US$ 393,000; and treatment costs for XDR TB averaged US$ 758,000.

Global Pyrazinamide Market - Impact of Coronavirus (COVID-19) Pandemic

The spread of the novel coronavirus has hampered growth of the healthcare industry. In December 2019, a cluster of pneumonia cases were reported by Chinese health authorities in China’s Wuhan City. The pneumonia causative agent was identified as a novel coronavirus named COVID-19. This virus spread rapidly across the globe causing a concerning number of fatalities. In March, 2020, the World Health Organization (WHO) declared COVID-19 as a global pandemic and suggested implementation of strict measures to minimize the spread of this disease. The pandemic has slowed growth of the healthcare sector and led to a disturbance in the supply chain of pharmaceutical drugs.

Moreover, governments across various countries have implemented nationwide lockdowns to curb the spread of COVID-19. Similarly, in various countries across the world, healthcare companies are facing problems of continuing their supply chain operations. The slowdown of the supply chain has also impacted growth of the global pyrazinamide market.

The global pyrazinamide market is estimated to be valued at US$ 143.9 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027).

Fig. 1. Global Pyrazinamide Market Share (%) Analysis, By Patient Type, 2020

Pyrazinamide  | Coherent Market Insights

Global Pyrazinamide Market- Restraints

Increasing pyrazinamide drug resistant TB infection is a major factor that is expected to restrain growth of the global pyrazinamide market.

request-sample

Pyrazinamide Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 143.9 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.6% 2027 Value Projection: US$ 163.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Patient Type: Adult, Pediatric.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.

Growth Drivers:
  • High burden of TB is driving growth of the market
Restraints & Challenges:
  • Increasing pyrazinamide drug resistant TB infection

Global Pyrazinamide Market: Regional Analysis

On the basis of region, the global pyrazinamide market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to witness significant growth in the global pyrazinamide market, owing to increasing number of TB patient across the U.S. and Canada respectively. For instance, in 2019, according to data of the Centers for Disease Control and Prevention states that, around 8,916 number of TB cases were reported in the U.S. Similarly, in 2017, according to the Canada government data, there were around 1,796 number of TB cases reported in Canada, when compared with around 1,750 number of TB cases in 2016, indicates a 2.6% increase.

Additionally, in Europe, growth of the pyrazinamide market is attributed to high number of TB patients. For instance, according to European Centre for Disease Prevention and Control data around 55,337 TB cases were reported in year 2017, which was around rate of 10.7 per 100,000 population.

Fig.2. Global Pyrazinamide Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Pyrazinamide  | Coherent Market Insights

Global Pyrazinamide Market- Competitive Landscape

Key players operating in the global pyrazinamide market include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, and, City Chemical.

Pyrazinamide (PZA) is a medication used to treat tuberculosis. Moreover, for active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol. It is not generally recommended for the treatment of latent tuberculosis. Pyrazinamide kills non-replicating persister cells that other medication of TB fail to kill, and for which it became important drug for inclusion in any drug combinations for treating drug susceptible and drug-resistant TB such as MDR-TB. It acts variably compared to other antibiotics by inhibiting energy production, trans-translation, and co-enzyme A required for persister survival. The increasing mutation in drug targeted gene is marking bacterial strain more resistant to PZA drug. The recently panD mutations gene was found along with pncA or rpsA mutations gene in bacterial resistant strains.

Market Dynamics

The high burden of TB is expected to drive growth of the market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa, which accounted for two thirds of the new TB cases.

The increasing global burden of TB is expected to drive the pyrazinamide market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.

Moreover, according to the WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$ 12 billion in additional economic costs and lost productivity. Thus, increasing healthcare spending on treatment of TB is expected to drive growth of the market.

Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.

Moreover, increasing investments in R&D activities for development of novel therapies for treatment of TB is expected to restrain growth of the pyrazinamide drugs market. For instance, according to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017, with an increase of 6% (or US$ 46 million), compared to US$ 726 million in 2016.

Key features of the study:

  • This report provides in-depth analysis of the global pyrazinamide market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
  • It profiles key players in the global pyrazinamide market  based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global pyrazinamide market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of Infertility drugs and devices, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Pyrazinamide Market, By Patient Type:
    • Adult
    • Pediatric
  • Global Pyrazinamide Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Pyrazinamide Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Patient Type:
        • Adult
        • Pediatric
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Patient Type:
        • Adult
        • Pediatric
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Patient Type:
        • Adult
        • Pediatric
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Patient Type:
        • Adult
        • Pediatric
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Patient Type:
        • Adult
        • Pediatric
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Patient Type:
        • Adult
        • Pediatric
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Pure Chemistry Scientific*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • LGM Pharma
    • City Chemical
    • TCI
    • HBCChem
    • Alfa Chemistry
    • Toronto Research Chemicals
    • Acros Organics
    • AlliChem
    • Waterstone Technology

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Patient Type
      • Market Snapshot, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Market Trends
    • Key Developments
    • Impact Analysis
    • Mergers & Acquisitions
    • New Product Launch
    • Technology Overview
    • PEST Analysis
  4. Global Pyrazinamide Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID 19 Impact Analysis
    • New Developments
  5. Global Pyrazinamide Market, By Patient Type, 2016 – 2027, (US$ million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Adult
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Pediatric
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Pyrazinamide Market, By Distribution Channel, 2016 – 2027, (US$ million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Pyrazinamide Market, By Region, 2016– 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
      • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
      • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
      • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
      • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
      • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
      • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
      • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Pure Chemistry Scientific
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • LGM Pharma
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • City Chemical
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • TCI
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • HBCChem
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Alfa Chemistry
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Toronto Research Chemicals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Acros Organics
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AlliChem
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Waterstone Technology
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 28 market data tables and 25 figures on "Global Pyrazinamide Market” - Forecast to 2027”

FAQgrowicon

Frequently Asked Questions

The global pyrazinamide market is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027).
The value of the global pyrazinamide market is estimated to be US$ 143.9 million in 2020.
The prominent players in the global pyrazinamide market include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.
The global pyrazinamide market is expected to be valued at US$ 163.1 million in 2027.
North America is the major region in the global pyrazinamide market.
Increasing high TB disease burden is expected to drive the global pyrazinamide market growth.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.